Article thumbnail

Pre-eclampsia: pathophysiology, diagnosis, and management

By Jennifer Uzan, Marie Carbonnel, Olivier Piconne, Roland Asmar and Jean-Marc Ayoubi


The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and morbidity, preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the pathophysiology of this multisystem disorder, characterized by abnormal vascular response to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for pre-eclampsia have not changed over the past decade (systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour proteinuria ≥0.3 g). Clinical features and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. Screening women at high risk and preventing recurrences are key issues in the management of pre-eclampsia

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2000). [No authors listed]. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy.
  2. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.
  3. Are perinatal and maternal outcomes different during expectant management of severe preeclampsia in the presence of intrauterine growth restriction?
  4. (2009). Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol.
  5. (1999). Corticosteroid therapy for prevention of respiratory distress syndrome in severe pre eclampsia.
  6. Diagnosis, prevention and management of eclampsia.
  7. (2006). Drugs for treatment of very high blood pressure during pregnacy. Cochrane Database Syst Rev.
  8. Early growth and coronary heart disease in later life: longitudinal study.
  9. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol.
  10. (1998). Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol.
  11. (1997). Epidemiology of pregnancy-induced hypertension. Epidemiol Rev.
  12. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
  13. (2009). Expectant management in pregnancies with severe pre eclampsia. Semin Perinatol.
  14. (1994). Expression of the nonclassic histocompatibility antigen HLA-G by preeclamptic placenta.
  15. (1992). Fetal death following labetalol administration in pre-eclampsia. Acta Obstet Gynecol Scand.
  16. First trimester uterine Doppler and three-dimensionnal ultrasound placental volume calculation in predicting pre-eclampsia.
  17. Genes and the preeclampsia syndrome.
  18. (1993). Growth in utero and serum cholesterol concentrations in adult
  19. High altitude during pregnancy.
  20. (2007). Hypertension and kidney disease in pregnancy.
  21. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
  22. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial.
  23. Infant growth and stroke in adult life: the Helsinki Birth Cohort Study.
  24. (1999). Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum Reprod.
  25. Long term mortality of mothers and fathers after pre eclampsia: population based cohort study.
  26. Long-term mortality after preeclampsia.
  27. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks’ gestation.
  28. (2008). Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess.
  29. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127(Suppl 3):S72–S75.
  30. (1999). Nitric oxide synthesis inhibition suppresses implantation and decreases CGMP concentration and protein peroxidation. Life Sci.
  31. Prediction and prevention of preeclampsia. Obstet Gynecol.
  32. Preeclampsia and future maternal health.
  33. Preeclampsia in the parous woman: who is at risk?
  34. Pregnancy complications and maternal risk of ischemic heart disease: a retrospective cohort study of 129,290 births.
  35. Pregnancy outcome in women presenting with pre-eclampsia at less than 25 weeks gestation.
  36. Prise en Charge Multidisciplinaire de la Prééclampsie. Issy Les Moulineaux, France:
  37. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy.
  38. Risk of preeclampsia in second-trimester triploid pregnancies. Obstet Gynecol.
  39. (2011). Royal College of Obstetricians and Gynaecologists. Pre-eclampsia – study group consensus statement. Available from: http://www.rcog. Accessed
  40. Severe preeclampsia at ,25 weeks of gestation: maternal and neonatal outcomes.
  41. (2009). The global impact of pre-eclampsia and eclampsia. Semin Perinatol.
  42. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study.
  43. The management of postpartum hypertension.
  44. (2009). The placenta in normal pregnancy and preeclampsia. In:
  45. (2005). Uterine artery Doppler at 11–14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol.
  46. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women.
  47. (2004). World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol.